DelistedDelistedDelisted
Liminal BioSciences Inc.
No trades
Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—
About Liminal BioSciences Inc.
Sector
Industry
CEO
Bruce Philip Pritchard
Website
Headquarters
East Belleville
Founded
1994
Identifiers
2
ISIN CA53272L2021
Liminal BioSciences, Inc. operates as a clinical stage biopharmaceutical company. The firm focuses on developing distinctive novel small molecule therapeutics for inflammatory, fibrotic, and metabolic diseases using drug discovery platform and a data driven approach. The firm has business operations in Canada and the United Kingdom. Its small molecule product candidate, fezagepras, has completed a Phase 1 multi-ascending dose clinical trial and anticipate conducting a comparative Phase 1a single ascending dose clinical trial to provide comparative data to support development plan. The company was founded on October 14, 1994 and is headquartered in Laval, Canada.
Related stocks
Frequently Asked Questions
Delisting occurs when a security is removed from a stock exchange, either voluntarily or involuntarily. It happens for various reasons: some companies do it as they cease all operations, others opt for it as the result of bankruptcy. Among other reasons there are merging with another company, failing to meet listing requirements, or the transition to private ownership.
A stock's fate depends on the way the company delisted. If it delisted voluntarily, its shareholders typically receive cash as a buyout or corresponding shares in the acquiring company. However, when a company is forced to delist, shareholders have to either find a buyer on the exchange, or keep holding shares of an unlisted company.
LMNL reached its all-time high on Apr 28, 2016 with the price of 27,739.00 USD, and its all-time low was 3.10 USD and was reached on Jan 3, 2023. View more price dynamics on LMNL chart.
See other stocks reaching their highest and lowest prices.
See other stocks reaching their highest and lowest prices.